Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

St Barbara Hospital selects Ablatherm-HIFU system to treat prostate cancers

EDAP TMS : 04 July, 2008  (Application Story)
EDAP TMS has agreed new revenue per procedure (RPP) contracts in Germany with St Barbara Hospital in Gladbeck and the Urological Clinic of the University of Heidelberg.
EDAP recently entered into a new RPP contract with St Barbara Hospital in Gladbeck. The centre has a history of commitment to exceptional patient care and cutting-edge research for the treatment of prostate cancer.

An initial HIFU trial session and workshop held in February 2008 gave urologists at the St Barbara Center the opportunity to assess Ablatherm technology and its robotic approach and evaluate patient benefits in comparison to more invasive treatment procedures. Initial feedback from the site positions Ablatherm-HIFU as a clinically proven choice for the treatment of localised prostate cancer as the number of procedures has continued to grow at the centre.

The company also entered into a longer term fixed RPP contract with the Urological Clinic of the University of Heidelberg. The centre's decision to sign the contract was based on a successful four-month trial period, which convinced urologists at the clinic of the clinical superiority and ease of use associated with the Ablatherm device.

Dr Sascha Pahernik, consultant of the Urological Clinic at the University of Heidelberg, commented, ``HIFU has the potential to become an important and viable treatment option for the treatment of localised prostate cancer due to the growing number of cases diagnosed each year. The clinical advantages of Ablatherm-HIFU as a minimally invasive, effective, and safe therapy position the treatment as a proven and valid technology in the modern urology practice.''

Judith Johannsen, general manager of EDAP in Germany, commented, ``We are strongly focused on carrying out targeted media outreach throughout the country. The recent peer review article from the French Association of Urology that positioned HIFU as a standard of care for the treatment of prostate cancer was widely distributed to help increase awareness of this proven technology among current and potential users in Germany.''

Marc Oczachowski, EDAP's chief executive officer, said, ``We are encouraged by the continued adoption of Ablatherm-HIFU across Germany, as exemplified by the recent addition of two new centres on a fixed and mobile RPP basis. We are all the more enthusiastic that these converted centres are world renowned clinical sites. The addition of these premier hospitals highlights the scientific community's acceptance of HIFU as a standard of care option for localised prostate cancer.''
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo